Recombinetics
Eagan
About Recombinetics
Recombinetics is a developer of gene editing technologies to improve human health through advanced disease models and regenerative medicine. Its gene-editing technologies manipulate deoxyribonucleic acid (DNA) samples to add and activate genes to solve problems and also offer gene repair and gene editing tools that enable biomedical research, livestock productivity, animal agriculture, and livestock vertical markets to modify animal genomes accurately and efficiently.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $67.9M
- Funding stage: Early Stage Venture
- Last round: Series A (Aug 2018)
- Website: recombinetics.com
- Phone: +1 612 727 2000
Industries & Categories
Biotechnology, Genetics, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/recombinetics-113186 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.